Prostate cancer | Talzenna | Xtandi | News | iPharmaCenter

October 4, 2022

Talzenna plus Xtandi showed improvement in PFS versus Xtandi.

Pfizer announced the positive Phase 3 TALAPRO-2 study results of Talzenna (talazoparib) plus Xtandi (enzalutamide) versus Xtandi plus placebo in patients with metastatic castration-resistant prostate cancer (mCRPC). Talzenna, an oral poly ADP-ribose polymerase (PARP) inhibitor, is under evaluation for mCRPC, with or without homologous recombination repair (HRR) gene mutations.

The study met the primary endpoint of demonstrating significant improvement in the radiographic progression-free survival (rPFS) versus Xtandi alone.

At the time of analysis, a progression towards the improvement in the overall survival was not met as the data was still immature. There was an improvement in the prostate-specific antigen (PSA) response, time to PSA progression, and overall response rate. The dose of Talzenna was 0.5mg/day, and Xtandi was 60mg/day.

Any regulatory agencies did not approve the combination for prostate cancer.


Recent Posts

See All